The company announces the opening of a satellite office in LondonLANDING, N.J., Sept. 13, 2023 /PRNewswire/ -- DolCas Biotech, LLC obtains its first Non-GMO Project-verified label for MMP-50®, a cold-processed, DNA-verified, and clinically researched New England green lipped mussel extract for human and pet health.

该公司宣布于2023年9月13日在新泽西州LondonLANDING开设卫星办公室/PRNewswire/--DolCas Biotech，LLC获得其首个非转基因项目验证标签MMP-50®，这是一种冷处理，经过DNA验证的，经过临床研究的新英格兰绿唇贻贝提取物，用于人体和宠物健康。

MMP-50 is one of seven clinically researched ingredients in the innovative company's portfolio, and while MMP-50 is the first to receive the backing of the prestigious certification, CEO and founder, K. G. Rao affirms the company's plans to pursue the certification across its portfolio..

MMP-50是创新公司产品组合中七种临床研究成分之一，而MMP-50是第一个获得着名认证支持的成分，首席执行官和创始人K.G.Rao肯定该公司计划在整个产品组合。。

Continue Reading

继续阅读

DolCas Biotech Obtains its First Non-GMO Project Verified Label for MMP-50®

DolCas Biotech获得其第一个针对MMP-50®的非转基因项目验证标签

The transparency efforts the Non-GMO Project spearheaded on the food front has translated to the supplement market. Recent Natural Marketing Institute data reveal that a non-GMO certification seal rates as high as a USDA Certified Organic seal, both leading the supplement purchasing decisions of consumers at 69%.

透明度努力非转基因生物项目带头食品前沿已转化为补充市场。最近的自然营销研究所数据显示，非转基因生物认证封印率高达美国农业部认证的有机封印率，两者都使消费者的补充购买决策达到69%。

A recent Nutraceuticals World article sharing the NMI data listed these two categories as leading by 10+ percentage points above USP, fair-trade, and NSF..

最近一篇分享NMI数据的营养保健品世界文章将这两个类别列为比USP，公平贸易和NSF高出10多个百分点的领先者。。

DolCas voluntarily submitted MMP-50 for compliance evaluation with the Non-GMO Project standard. 'Given the pristine conditions of the New Zealand waters, the mussel farming practices that are tightly regulated by the local authorities, and the consistent quality of this ingredient, we were confident that MMP-50 would meet the high standards and rigorous accounting required of the project's product verification program,' conveyed Rao..

DolCas自愿提交MMP-50，以符合非转基因生物项目标准的合规性评估鉴于新西兰水域的原始条件，受地方当局严格监管的贻贝养殖方式以及该成分的一致质量，我们相信MMP-50将符合该项目所需的高标准和严格会计。产品验证计划，“传达饶。。

MMP50™ is produced from fresh, unopened mussels supplied directly from the ocean farm to the factory with no middle-man or traveling delay. Further, the shell extraction step is time/temperature controlled to maintain biological activity throughout the processing.'This verification is just one of the components of the impressive marketing suite backing MMP-50,' adds Shavon Jackson-Michel, Director of Medical and Scientific Affairs for DolCas.

MMP50™ 由直接从海洋农场供应到工厂的新鲜未开封贻贝生产，没有中间人或旅行延误。此外，壳提取步骤是时间/温度控制的，以在整个加工过程中保持生物活性DolCas医学和科学事务总监Shavon Jackson Michel补充说，这种验证只是支持MMP-50的令人印象深刻的营销套件的组成部分之一。

'Each batch of MMP-50 is tested for DNA to validate exclusive Perna canaliculus—Green Lipped Mussel—sourcing, against adulterated and counterfeit mussel preparations from blue, black, and even brown shell varieties. The proprietary, cold-processed whole-mussel extract boasts a unique, fully-preserved spectrum of synergistically active compounds, including protein, lipids, anti-inflammatory omega-3s, carbohydrates—including joint supportive glycosaminoglycans—and a host of vitamins, minerals, and other micronutrients.

'每批MMP-50都经过DNA测试，以验证独家的Perna小管绿唇贻贝来源，针对来自蓝色，黑色甚至棕色贝壳品种的掺假和假冒贻贝制剂。专有的冷加工全贻贝提取物拥有独特的，完全保存的协同活性化合物谱，包括蛋白质，脂质，抗炎ω-3，碳水化合物，包括关节支持性糖胺聚糖和许多维生素，矿物质和其他微量营养素。

This distinguishes MMP-50 from other green lipped mussel extracts in the market that are either cooked, or solvent-extracted, concentrated lipid fractions, or defatted formulations that upcycle remnant components of the green lipped mussel after the lipids have been isolated.'Non-GMO project verification further sets MMP-50 apart in the market in combination with the formulation's published clinical support in humans, dogs, and horses for reducing joint discomfort and limitation, promoting extended active lifestyles/activity, and supporting joint function.

这将MMP-50与市场上其他绿色贻贝提取物区分开来，这些提取物是煮熟的或溶剂提取的浓缩脂质部分或脱脂制剂，其在分离脂质后循环绿色贻贝的残余成分非转基因生物项目验证进一步将MMP-50在市场上与配方在人类，狗和马中公布的临床支持相结合，以减少关节不适和限制，促进延长的积极生活方式/活动，并支持关节功能。

Each batch of MMP-50 produced is further assayed for bioactivity and screened against nine relevant, joint-destructive enzymes, known as matrix metalloproteinases (MMPs). MMP-50 is proven to consistently inhibit them by a minimum of 50%. 'We wanted to do our part in .

进一步测定产生的每批MMP-50的生物活性，并针对称为基质金属蛋白酶（MMP）的九种相关的关节破坏性酶进行筛选。MMP-50被证明能够持续抑制它们至少50%我们想参与其中。